Survivin expression in oesophageal squamous cell carcinoma: its prognostic impact and splice variant expression

European Journal of Cardio-thoracic Surgery

Volumn 37, Issue 2, 2010, Pages 440-445

  Takeno, Shinsuke ^a   Yamashita, Shin ichi ^a   Takahashi, Yoshiaki ^a   Ono, Kiyoshi ^a   Kamei, Mirei ^a   Moroga, Toshihiko ^a   Kawahara, Katsunobu ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Oesophageal squamous cell carcinoma; Prognosis; Survivin; Survivin 2B; Survivin deltaEx3

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; SURVIVIN; SURVIVIN 2B; SURVIVIN DELTA EX3; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INVASION; CANCER PATIENT; CELL NUCLEUS; CYTOPLASM; ESOPHAGUS CARCINOMA; FEMALE; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CYTOPLASM; EPIDEMIOLOGIC METHODS; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 74149083250     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2009.05.056     Document Type: Article

References (19)

1. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
2. Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., Tenjo T., and Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58 (1998) 5071-5074
3. Monzo M., Rosell R., Felip E., Astudillo J., Sanchez J.J., Maestre J., Martin C., Font A., Barnadas A., and Abad A. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17 (1999) 2100-2104
4. Mahotka C., Wenzel M., Springer E., Gabbert H.E., and Gerharz C.D. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59 (1999) 6097-6102
5. Krieg A., Mahotka C., Krieg T., Grabsch H., Muller W., Takeno S., Suschek C.V., Heydthausen M., Gabbert H.E., and Gerharz C.D. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 86 (2002) 737-743
6. Mayer R.J. Overview: the changing nature of esophageal cancer. Chest 103 (1993) 404S-405S
7. Kato J., Kuwabara Y., Mitani M., Shinoda N., Sato A., Toyama T., Mitsui A., Nishiwaki T., Moriyama S., Kudo J., and Fujii Y. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95 (2001) 92-95
8. Ikeguchi M., and Kaibara N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer 87 (2002) 883-887
9. Grabowski P., Kuhnel T., Muhr-Wilkenshoff F., Heine B., Stein H., Hopfner M., Germer C.T., and Scherubl H. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 88 (2003) 115-119
10. Dabrowski A., Filip A., Zgodzinski W., Dabrowska M., Polanska D., Wojcik M., Zinkiewicz K., and Wallner G. Assessment of prognostic significance of cytoplasmic survivin expression in advanced oesophageal cancer. Folia Histochem Cytobiol 42 (2004) 169-172
11. Vallbohmer D., Peters J.H., Oh D., Kuramochi H., Shimizu D., Demeester S.R., Hagen J.A., Chandrasoma P.T., Danenberg K.D., DeMeester T.R., and Danenberg P. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma. Surgery 138 (2005) 701-706 discussion 706-7
12. Rosato A., Pivetta M., Parenti A., Iaderosa G.A., Zoso A., Milan G., Mandruzzato S., Del Bianco P., Ruol A., Zaninotto G., and Zanovello P. Survivin in esophageal cancer: an accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer 119 (2006) 1717-1722
13. Mega S., Miyamoto M., Li L., Kadoya M., Takahashi R., Hase R., Kaneko H., Shichinohe T., Kawarada Y., Itoh T., Morikawa T., and Kondo S. Immunohistochemical analysis of nuclear survivin expression in esophageal squamous cell carcinoma. Dis Esophagus 19 (2006) 355-359
14. Pisani P., Parkin D.M., Bray F., and Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83 (1999) 18-29
15. In: Sobin L.H., and Wittekind Ch. (Eds). UICC TNM classification of malignant tumours. Fifth edition (1997), Wiley-Liss, New York 54-58
16. Warnecke-Eberz U., Hokita S., Xi H., Higashi H., Baldus S.E., Metzger R., Brabender J., Bollschweiler E., Mueller R.P., Dienes H.P., Hoelscher A.H., and Schneider P.M. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 13 (2005) 1241-1246
17. Hirohashi Y., Torigoe T., Maeda A., Nabeta Y., Kamiguchi K., Sato T., Yoda J., Ikeda H., Hirata K., Yamanaka N., and Sato N. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 8 (2002) 1731-1739
18. Tsuruma T., Hata F., Torigoe T., Furuhata T., Idenoue S., Kurotaki T., Yamamoto M., Yagihashi A., Ohmura T., Yamaguchi K., Katsuramaki T., Yasoshima T., Sasaki K., Mizushima Y., Minamida H., Kimura H., Akiyama M., Hirohashi Y., Asanuma H., Tamura Y., Shimozawa K., Sato N., and Hirata K. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2 (2004) 19
19. Ichiki Y., Hanagiri T., Takenoyama M., Baba T., Fukuyama T., Nagata Y., Mizukami M., So T., Sugaya M., Yasuda M., So T., Sugio K., and Yasumoto K. Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy. Lung Cancer 48 (2005) 281-289